(LXS) LANXESS Aktiengesellschaft - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE0005470405
LXS: Chemicals, Additives, Intermediates, Protection, Purification
LANXESS Aktiengesellschaft, a global leader in specialty chemicals, specializes in the development, production, and distribution of high-performance chemical intermediates, additives, and consumer protection products. The company, established in 1863 and headquartered in Cologne, Germany, organizes its operations into three core segments: Consumer Protection, Specialty Additives, and Advanced Intermediates. Each segment serves distinct markets, leveraging LANXESSs expertise in chemical innovation and sustainability.
The Consumer Protection segment delivers a diverse portfolio of solutions, including material protection products, disinfectants, and preservatives. It also offers advanced water treatment technologies and intermediates for the pharmaceutical and agrochemical industries. This segment is critical for industries requiring high-performance, reliable chemical solutions to ensure product safety and durability.
The Specialty Additives segment focuses on enhancing the performance of materials used in various industries. It provides flame retardants, plasticizers, and lubricants, among other additives, tailored for applications in the automotive, construction, and electronics sectors. This segment underscores LANXESSs commitment to improving material efficiency and safety across multiple industrial applications.
The Advanced Intermediates segment produces basic and fine chemicals, organometallics, and inorganic pigments. These products are essential for the production of agrochemicals, semiconductors, and construction materials. This segment highlights LANXESSs role as a key supplier to industries requiring specialized chemical building blocks.
LANXESS Aktiengesellschaft operates with a strong emphasis on innovation and sustainability, aligning its business practices with global environmental and regulatory standards. Its extensive product portfolio and global distribution network position it as a critical player in the specialty chemicals market.
3-Month Forecast: Based on
Additional Sources for LXS Stock
LXS Stock Overview
| Market Cap in USD | 2,505m |
| Sector | Basic Materials |
| Industry | Specialty Chemicals |
| GiC Sub-Industry | Specialty Chemicals |
| IPO / Inception |
LXS Stock Ratings
| Growth Rating | -35.3 |
| Fundamental | -28.3 |
| Dividend Rating | 6.36 |
| Rel. Strength | 1.12 |
| Analysts | - |
| Fair Price Momentum | 23.02 EUR |
| Fair Price DCF | 40.75 EUR |
LXS Dividends
| Dividend Yield 12m | 0.78% |
| Yield on Cost 5y | 0.51% |
| Annual Growth 5y | -36.25% |
| Payout Consistency | 88.9% |
LXS Growth Ratios
| Growth Correlation 3m | -39.2% |
| Growth Correlation 12m | 34.2% |
| Growth Correlation 5y | -84.7% |
| CAGR 5y | -7.67% |
| CAGR/Max DD 5y | -0.11 |
| Sharpe Ratio 12m | -0.79 |
| Alpha | -15.75 |
| Beta | 0.819 |
| Volatility | 50.42% |
| Current Volume | 300.6k |
| Average Volume 20d | 383.5k |
As of May 02, 2025, the stock is trading at EUR 26.22 with a total of 300,613 shares traded.
Over the past week, the price has changed by +3.64%, over one month by -5.48%, over three months by +0.92% and over the past year by -2.43%.
Probably not. Based on ValueRay Fundamental Analyses, LANXESS Aktiengesellschaft (XETRA:LXS) is currently (May 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.29 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LXS as of May 2025 is 23.02. This means that LXS is currently overvalued and has a potential downside of -12.2%.
LANXESS Aktiengesellschaft has no consensus analysts rating.
According to ValueRays Forecast Model, LXS LANXESS Aktiengesellschaft will be worth about 24.9 in May 2026. The stock is currently trading at 26.22. This means that the stock has a potential downside of -4.92%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 28.5 | 8.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 24.9 | -4.9% |